LSLiyan Y. Smeding

Liyan Y. Smeding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liyan Y. Smeding has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Ashraful Islam

    Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, USA

    1 shared publication
  • Gualberto Gonzalez-Sapienza

    Cátedra de Inmunología, Departamento de Biociencias (DEPBIO), Facultad de Química, Universidad de la República, Montevideo, Uruguay

    1 shared publication
  • Harun R. Sugito

    Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, USA

    1 shared publication
  • Hidde Lolke Ploegh

    Program in Cellular and Molecular Medicine, Boston Children’s Hospital

    1 shared publication
  • Leif S. Ludwig

    Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Martin A. Rossotti

    Cátedra de Inmunología, Departamento de Biociencias (DEPBIO), Facultad de Química, Universidad de la República, Montevideo, Uruguay

    1 shared publication

Latest Publications

  • Induction of antigen-specific tolerance by nanobody–antigen adducts that target class-II major histocompatibility complexes

    by Novalia Pishesha, Thibault Harmand, Liyan Y. Smeding, Weiyi Ma, Leif S. Ludwig, Robine Janssen, Ashraful Islam, Yushu J. Xie, Tao Fang, Nicholas McCaul, et al.

    The association of autoimmune diseases with particular allellic products of the class-II major histocompatibility complex (MHCII) region implicates the presentation of the offending self-antigens to T cells. Because antigen-presenting cells are tolerogenic when they encounter an antigen under non-inflammatory conditions, the manipulation of antigen presentation may induce antigen-specific tolerance. Here, we show that, in mouse models of experimental autoimmune encephalomyelitis, type 1 diabetes and rheumatoid arthritis, the systemic administration of a single dose of nanobodies that recognize MHCII molecules and conjugated to the relevant self-antigen under non-inflammatory conditions confers long-lasting protection against these diseases. Moreover, co-administration of a nanobody–antigen adduct and the glucocorticoid dexamethasone, conjugated to the nanobody via a cleavable linker, halted the progression of established experimental autoimmune encephalomyelitis in symptomatic mice and alleviated their symptoms. This approach may represent a means of treating autoimmune conditions.